SAN DIEGO, Feb. 14, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC) today announced that there will be multiple presentations on GIAPREZA (angiotensin II) at the Society of Critical Care Medicine’s (SCCM) 48th Critical Care Congress to be held February 17 - 20, 2019 in San Diego, CA. Abstracts for the oral presentations are publicly available and can be found on the SCCM website and by clicking the titles below.

Presentation Details:

Product Theater Presentation:   GIAPREZA (angiotensin II), A Novel Treatment Option for Septic or Other Distributive Shock
Presenter: Professor Bruce Friedman, MD, CNSP, FCCP, FCCM Critical Care and Co-Director
  JM Still Burn Center Augusta, GA and Augusta University Medical Center 
Presentation Date/Time:  Monday, February 18, 2019 / 8:45 am PST
Session Room: Theater 2
   
Oral Presentation Title:   Effect of Angiotensin II on Vasopressor Dose and Safety in Patients with Severe Vasodilatory Shock
Presenter: Paula Ferrada, MD
  Virginia Commonwealth University School of Medicine, Richmond, VA
Session Title:    Research Snapshot: Sepsis IX
Oral Presentation Date/Time:  Monday, February 18, 2019 / 2:30 pm - 3:30 pm PST
Session Room:  Research Snapshot Theater 15 (Hall GH)
   
Oral Presentation Title:  Juvenile Developmental Toxicity of LJPC-501 (angiotensin II) in Newborn Sheep
Presenter:   Sima Patel BS MS, La Jolla Pharmaceutical Company 
Session Title: Research Snapshot: Veterinary I
Oral Presentation Date/Time: Tuesday, February 19, 2019 / 8:45 am - 9:45 am PST
Session Room:  Research Snapshot Theater 12 (Hall GH)
   
Oral Presentation Title:  Time Below Map Threshold in First 24 Hours of Initiation of Vasopressor Therapy and Mortality
Presenter:   Nathan Nielsen, MD, MSc
  Tulane University School of Medicine, New Orleans, LA
Session Title:  Research Snapshot: Sepsis XI
Oral Presentation Date/Time:    Tuesday, February 19, 2019 / 10:00 am - 11:00 am PST
Session Room:    Research Snapshot Theater 15 (Hall GH)
   
Oral Presentation Title:    Outcomes in Patients with Postoperative Vasoplegia Receiving Angiotensin II for Vasodilatory Shock
Presenter:  Bruce Friedman, MD, CNSP, FCCP, FCCM
  Joseph M. Still Burn Center, Augusta, GA
Session Title:  Research Snapshot: Sepsis XII
Oral Presentation Date/Time:  Tuesday, February 19, 2019 / 11:15 am - 12:15 am PST
Session Room: Research Snapshot Theater 15 (Hall GH)

About GIAPREZA

In December 2017, GIAPREZA™ (angiotensin II) was approved by the U.S. Food and Drug Administration (FDA) as a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock. GIAPREZA mimics the body’s endogenous regulatory peptide that is central to the renin-angiotensin-aldosterone system to increase blood pressure. Prescribing information for GIAPREZA is available at www.giapreza.com . GIAPREZA is marketed by La Jolla Pharmaceutical Company on behalf of La Jolla Pharma, LLC, its wholly owned subsidiary.

IMPORTANT SAFETY INFORMATION

Contraindications

None

Warnings and Precautions

There is a potential for venous and arterial thrombotic and thromboembolic events in patients who receive GIAPREZA. Use concurrent venous thromboembolism (VTE) prophylaxis.

Adverse Reactions

The most common adverse reactions that were reported in greater than 10% of GIAPREZA-treated patients were thromboembolic events.

Drug Interactions

Angiotensin converting enzyme (ACE) inhibitors may increase response to GIAPREZA. Angiotensin II receptor blockers (ARB) may reduce response to GIAPREZA.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch  or call 1-800-FDA-1088.

For additional information, please see Full Prescribing Information .

About La Jolla Pharmaceutical Company

La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. GIAPREZA™ (angiotensin II), formerly known as LJPC-501, was approved by the U.S. Food and Drug Administration (FDA) on December 21, 2017 as a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock. LJPC-0118 is La Jolla’s investigational product for the treatment of severe malaria. LJPC‑401 (synthetic human hepcidin), a clinical-stage investigational product, is being developed for the potential treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease and myelodysplastic syndrome. For more information, please visit www.ljpc.com .

Forward-looking Statements

This press release contains forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements relate to expectations regarding future events or La Jolla’s future results of operations. These statements are only predictions or statements of current expectations and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those anticipated by the forward-looking statements. La Jolla cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. Certain of these risks, uncertainties and other factors are described in greater detail in La Jolla’s filings with the U.S. Securities and Exchange Commission (SEC), all of which are available free of charge on the SEC’s website  www.sec.gov . These risks include, but are not limited to, risks relating to: clinical studies with GIAPREZA may not be successful in evaluating their safety and tolerability or providing evidence of efficacy; unforeseen safety issues from the administration of GIAPREZA in patients; the anticipated treatment of future clinical data by the FDA, the EMA or other regulatory authorities; potential market sizes, including for septic or other distributive shock; our ability to successfully commercialize, market and achieve market acceptance of GIAPREZA; and other risks and uncertainties identified in our filings with the SEC. La Jolla expressly disclaims any intent to update any forward‑looking statements to reflect the outcome of subsequent events.

Company Contacts

Sandra Vedrick Director, Investor Relations & Human Resources La Jolla Pharmaceutical Company Phone: (858) 207-4264 Ext: 1135 Email: svedrick@ljpc.com

and

Dennis M. Mulroy Chief Financial Officer La Jolla Pharmaceutical Company Phone: (858) 207-4264 Ext: 1040 Email: dmulroy@ljpc.com